Shanghai Fosun Pharmaceutical (Group) Management
Management criteria checks 4/4
Shanghai Fosun Pharmaceutical (Group)'s CEO is Deyong Wen, appointed in Jan 2022, has a tenure of 3.33 years. total yearly compensation is CN¥4.09M, comprised of 63.4% salary and 36.6% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth €445.81K. The average tenure of the management team and the board of directors is 2.6 years and 3.9 years respectively.
Key information
Deyong Wen
Chief executive officer
CN¥4.1m
Total compensation
| CEO salary percentage | 63.38% |
| CEO tenure | 3.3yrs |
| CEO ownership | 0.006% |
| Management average tenure | 2.6yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | CN¥3b |
| Dec 31 2024 | CN¥4m | n/a | CN¥3b |
| Sep 30 2024 | n/a | n/a | CN¥2b |
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥10m | CN¥3m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥8m | CN¥2m | CN¥4b |
Compensation vs Market: Deyong's total compensation ($USD567.70K) is below average for companies of similar size in the German market ($USD2.85M).
Compensation vs Earnings: Deyong's compensation has been consistent with company performance over the past year.
CEO
Deyong Wen (53 yo)
3.3yrs
Tenure
CN¥4,091,000
Compensation
Mr. Deyong Wen served as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022 until April 29, 2025 and serves as Vice chairman since April 29, 2025. He has been a Non-...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | less than a year | no data | 0.0058% € 415.1k | |
| Joint President | 3.3yrs | CN¥4.09m | 0.0063% € 445.8k | |
| Executive President & Chief Human Resources Office | 1.3yrs | CN¥2.36m | 0.0031% € 222.6k | |
| Executive President | 2.3yrs | CN¥9.86m | no data | |
| Executive President & Co-CEO of Innovative Drug Division | 2.3yrs | CN¥10.24m | no data | |
| Executive Director | 2.9yrs | CN¥5.34m | 0.015% € 1.1m | |
| Senior VP & CFO | less than a year | CN¥2.64m | 0.0013% € 89.2k | |
| Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee | 4.2yrs | CN¥2.17m | 0.0016% € 117.0k | |
| Senior VP & Chief Strategic Enabler | 4.6yrs | CN¥2.51m | 0.0031% € 222.6k | |
| Senior VP and Chairman & CEO of Medical Devices and Diagnostics Division | 3.3yrs | CN¥2.73m | 0.0019% € 138.4k | |
| Senior Vice President | 3.3yrs | CN¥1.97m | 0.00076% € 54.2k | |
| VP & Co-CEO of Medical Device Division | 1.9yrs | CN¥3.11m | no data |
2.6yrs
Average Tenure
53yo
Average Age
Experienced Management: 08HH's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | less than a year | no data | 0.0058% € 415.1k | |
| Joint President | 2.8yrs | CN¥4.09m | 0.0063% € 445.8k | |
| Executive Director | 3.4yrs | CN¥5.34m | 0.015% € 1.1m | |
| Independent Non-Executive Director | 5.9yrs | CN¥392.00k | no data | |
| Non-Executive Director | 20yrs | no data | 0.0043% € 307.4k | |
| Co-Chairman | 3.4yrs | CN¥3.71m | 0.013% € 960.1k | |
| Non-Executive Director | 5.9yrs | no data | no data | |
| Non-Executive Director | 8.8yrs | CN¥12.14m | 0.049% € 3.5m | |
| Independent Non-Executive Director | 5.9yrs | CN¥400.00k | no data | |
| Independent Non-Executive Director | 3.9yrs | CN¥400.00k | no data | |
| Independent Non-Executive Director | 3.9yrs | CN¥400.00k | no data | |
| Chief Supervisor | 1.9yrs | no data | no data |
3.9yrs
Average Tenure
54yo
Average Age
Experienced Board: 08HH's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 16:51 |
| End of Day Share Price | 2025/04/01 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Yang Huang | BofA Global Research |
| Pei Cheng | China Galaxy Securities Co., Ltd. |